INBRAIN Neuroelectronics Raises $50 Million to Advance Graphene-Based Brain-Computer Interface Technology

INBRAIN Neuroelectronics, a Spanish firm specializing in graphene-based brain-computer interface (BCI) technologies, has secured $50 million in a Series B financing round. This funding will propel the development of INBRAIN's neural interface technology, including advancing clinical trials and commercial production. The investment, led by imec.xpand, also involves participation from new investors and existing stakeholders. INBRAIN aims to enhance its AI-driven platform for treating neurological disorders and strengthen its team.

In a groundbreaking development, Spanish firm INBRAIN Neuroelectronics has announced the successful completion of a $50 million Series B financing round. This substantial investment will accelerate the company's progress in creating advanced neural interface technology, with a focus on enhancing its AI-driven platform for treating neurological disorders and expanding its team [1].

With neurological disorders affecting a significant percentage of the global population and ranking as the leading cause of disability and the second cause of mortality worldwide, the need for innovative solutions is undeniable [1]. INBRAIN's technology aims to address these challenges by providing non-invasive, high-resolution brain-computer interfaces (BCIs) that enable real-time smart neural decoding and modulation in closed loop [1].

The company's end-to-end neural platform combines hardware and data analytics to decode and modulate neural networks, optimizing time on therapy and effectively restoring function or mobility for patients [1]. INBRAIN's BCI technology is also skin-like, bi-directional, and high resolution, delivering unparalleled signal resolution that enhances treatment efficiency [1].

INBRAIN's technology utilizes graphene, a versatile material with unique properties that enable the development of flexible, high-resolution, high-precision implantable neurotechnology [2]. Graphene also offers several advantages, such as high charge injection capacity and low electrical impedance, which significantly reduce power requirements and drive miniaturization for enhanced patient comfort [2].

The investment, led by imec.xpand, also includes participation from new investors and existing stakeholders [1]. INBRAIN's mission extends beyond decoding and modulating the brain, as the company also aims to revolutionize the entire neural system [1].

With FDA Breakthrough Device Designation for use in Parkinson's Disease [1], INBRAIN's technology represents a significant leap forward in the treatment of neurological disorders. The company's innovative approach, combined with the support of its investors, positions it for continued success in the development and commercialization of its neural interface technology.

References:
[1] INBRAIN Neuroelectronics. (n.d.). Retrieved March 29, 2023, from https://inbrain-neuroelectronics.com/
[2] INBRAIN Neuroelectronics. (n.d.). Neuroelectronic Therapies. Retrieved March 29, 2023, from https://inbrain-neuroelectronics.com/neuroelectronic-therapies/
[3] INBRAIN Neuroelectronics. (2021, March 17). Announcing First Human Implant of Graphene-Based Brain Computer Interface. Retrieved March 29, 2023, from https://inbrain-neuroelectronics.com/news/announcing-first-human-implant-of-graphene-based-brain-computer-interface/